Research In Brief
No to knee 'scoping: Arthroscopic knee surgery for osteoarthritis provides no additional benefits to optimized physical and medical therapy alone, according to the results of a Canadian study appearing in the Sept. 11 issue of the New England Journal of Medicine. Researchers at the University of Western Ontario randomized 178 patients with moderate-to-severe osteoarthritis of the knee to either surgical lavage and arthroscopic debridement plus physical and medical therapy or physical and medical therapy alone. After two years, the mean scores for both groups on the Western Ontario and McMaster Universities Osteoarthritis (WOMAC) Index were almost the same: 874 for the surgery group and 897 for the control group. Analysis of the WOMAC scores and other secondary endpoints also showed no superiority for surgery. The results of this study on top of several previous studies on arthroscopic knee lavage and debridement "call into question the widespread use of arthroscopic treatment for osteoarthritis of the knee," Alexandra Kirkley et al. write. They also observe that "although some may argue that treatment is beneficial for patients with mechanical symptoms of catching or locking or those with early disease, prespecified subgroup analyses also failed to show efficacy in this population of patients.
More from Archive
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.
Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.
In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.
More from Medtech Insight
An interactive look at medtech and diagnostics deals made during June 2025. Data courtesy of Biomedtracker.
Medtech companies require expertise to navigate complex AI regulations and integrate AI in medical software while addressing regulatory challenges, claims expert AI consultant with medtech experience.
A surgeon at Ochsner Health in New Orleans was able to successfully remove a rare and dangerous tumor from a patient’s spine using cutting-edge technology that would have otherwise made the procedure too risky.